| Market Capitalization (Millions $) |
4 |
| Shares
Outstanding (Millions) |
6 |
| Employees |
52 |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
-42 |
| Cash Flow (TTM) (Millions $) |
3 |
| Capital Exp. (TTM) (Millions $) |
0 |
Business Description
Moleculin Biotech Inc is a clinical-stage biopharmaceutical company that focuses on the development of novel cancer therapies. The company is dedicated to addressing unmet medical needs through the development of potentially life-saving drugs. They primarily target highly resistant tumors with their proprietary small molecule technology platform.
Moleculin Biotech has a pipeline of multiple drug candidates, including Annamycin, WP1122, and WP1066, which have shown promising results in preclinical and early clinical studies. These candidates are designed to target specific proteins or tumor types, inhibiting tumor growth and promoting cancer cell death.
The company's flagship drug candidate, Annamycin, is being developed for the treatment of relapsed or refractory acute myeloid leukemia (AML) and has shown potential to bypass multidrug resistance mechanisms observed in other chemotherapies. Moleculin Biotech is also exploring the potential applications of their technology platform in other types of cancer such as glioblastoma, pancreatic, and lung cancer.
In addition to their drug development efforts, Moleculin Biotech also collaborates with leading research institutions and cancer clinics to conduct clinical trials and further explore the potential of their drug candidates. The company aims to make a significant impact in the field of oncology by developing innovative therapies that can improve patient outcomes and quality of life.
Company Address: 5300 Memorial Drive, Suite 950 Houston 77007 TX
Company Phone Number: 300-5160 Stock Exchange / Ticker: NASDAQ MBRX
|
